SCYNEXIS, Inc. (SCYX) financial statements (2021 and earlier)

Company profile

Business Address 1 EVERTRUST PLAZA
JERSEY CITY, NJ 07302-6548
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments48283539444955
Cash and cash equivalents4212191311167
Short-term investments6161626333348
Restricted cash and investments  0000 
Receivables     00
Prepaid expense0110000
Other current assets1000000
Other undisclosed current assets3001701
Total current assets:52293640515057
Noncurrent Assets
Operating lease, right-of-use asset33  
Property, plant and equipment0000100
Restricted cash and investments0000000
Deferred costs0000000
Other noncurrent assets1111111
Other undisclosed noncurrent assets  33   
Total noncurrent assets:5555212
TOTAL ASSETS:57344145535258
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11875634
Accounts payable7642423
Accrued liabilities4232212
Debt00   75
Derivative instruments and hedges, liabilities     03
Other undisclosed current liabilities  00000
Total current liabilities:1187561113
Noncurrent Liabilities
Long-term debt and lease obligation33  1589
Long-term debt, excluding current maturities    1589
Operating lease, liability33  
Other undisclosed noncurrent liabilities30162329159
Total noncurrent liabilities:33202329161318
Total liabilities:44283134222431
Stockholders' equity
Stockholders' equity attributable to parent, including:1361011312827
Additional paid in capital284263259252249247247
Accumulated deficit(271)(257)(249)(241)(218)(220)(220)
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:1361011312827
TOTAL LIABILITIES AND EQUITY:57344145535258

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:  00000
Operating expenses(14)(12)(11)(12)(9)(6)(8)
Operating loss:(14)(12)(11)(12)(9)(6)(8)
Nonoperating income (expense)(0)43(11)47(3)
Investment income, nonoperating 21(3)(0)  
Interest and debt expense (0)(0)(1)(0)(0)(0)
Loss from continuing operations before equity method investments, income taxes:(14)(8)(9)(24)(5)(0)(11)
Other undisclosed income from continuing operations before income taxes1   2  
Loss from continuing operations before income taxes:(13)(8)(9)(24)(4)(0)(11)
Other undisclosed income from continuing operations    7  
Income (loss) before gain (loss) on sale of properties:(13)(8)(9)(24)3(0)(11)
Other undisclosed net income (loss)(1)  1(1)  
Net income (loss):(14)(8)(9)(23)2(0)(11)
Other undisclosed net income attributable to parent 00  00
Net income (loss) available to common stockholders, basic:(14)(8)(8)(23)20(11)
Dilutive securities, effect on basic earnings per share (2)     
Net income (loss) available to common stockholders, diluted:(14)(10)(8)(23)20(11)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):(14)(8)(9)(23)2(0)(11)
Comprehensive income (loss), net of tax, attributable to parent:(14)(8)(9)(23)2(0)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: